fda sued over tirzepatide FDA's decision creates uncertainty for patients—and leads to a lawsuit FDA reconsidering its decision to

Limitations & Unknowns While promising, there remain many uncertainties: Causality not yet proven : Many studies are associative

Nicaise has been off Contrave for a year and has gained back 15 pounds

In reality, long-term wellness still depends on daily routines and lifestyle balance

The full QC panel includes heavy metals analysis (all Not Detected), sterility testing via PCR (No Growth), and a negative fentanyl screen

The primary endpoint was to demonstrate non-inferiority (with a non-inferiority margin of 0.3%) of tirzepatide 10 mg or 15 mg, or both, compared to glargine in terms of the change in HbA1c from baseline to 52 weeks